vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Grand Canyon Education, Inc. (LOPE). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). Grand Canyon Education, Inc. runs the higher net margin — 28.1% vs -0.7%, a 28.9% gap on every dollar of revenue. On growth, Grand Canyon Education, Inc. posted the faster year-over-year revenue change (5.3% vs 0.7%). Grand Canyon Education, Inc. produced more free cash flow last quarter ($122.9M vs $21.3M). Over the past eight quarters, Grand Canyon Education, Inc.'s revenue compounded faster (5.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
AVNS vs LOPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $308.1M |
| Net Profit | $-1.3M | $86.7M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 35.1% |
| Net Margin | -0.7% | 28.1% |
| Revenue YoY | 0.7% | 5.3% |
| Net Profit YoY | 99.7% | 5.9% |
| EPS (diluted) | $-0.02 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $308.1M | ||
| Q3 25 | $177.8M | $261.1M | ||
| Q2 25 | $175.0M | $247.5M | ||
| Q1 25 | $167.5M | $289.3M | ||
| Q4 24 | $179.6M | $292.6M | ||
| Q3 24 | $170.4M | $238.3M | ||
| Q2 24 | $171.7M | $227.5M | ||
| Q1 24 | $166.1M | $274.7M |
| Q4 25 | $-1.3M | $86.7M | ||
| Q3 25 | $-1.4M | $16.3M | ||
| Q2 25 | $-76.8M | $41.5M | ||
| Q1 25 | $6.6M | $71.6M | ||
| Q4 24 | $-397.3M | $81.9M | ||
| Q3 24 | $4.3M | $41.5M | ||
| Q2 24 | $1.8M | $34.9M | ||
| Q1 24 | $-900.0K | $68.0M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 35.1% | ||
| Q3 25 | 0.1% | 6.9% | ||
| Q2 25 | -42.6% | 20.9% | ||
| Q1 25 | 6.1% | 30.4% | ||
| Q4 24 | -233.0% | 34.2% | ||
| Q3 24 | 7.0% | 20.2% | ||
| Q2 24 | 3.7% | 18.8% | ||
| Q1 24 | 2.4% | 30.8% |
| Q4 25 | -0.7% | 28.1% | ||
| Q3 25 | -0.8% | 6.2% | ||
| Q2 25 | -43.9% | 16.8% | ||
| Q1 25 | 3.9% | 24.8% | ||
| Q4 24 | -221.2% | 28.0% | ||
| Q3 24 | 2.5% | 17.4% | ||
| Q2 24 | 1.0% | 15.3% | ||
| Q1 24 | -0.5% | 24.8% |
| Q4 25 | $-0.02 | $3.13 | ||
| Q3 25 | $-0.03 | $0.58 | ||
| Q2 25 | $-1.66 | $1.48 | ||
| Q1 25 | $0.14 | $2.52 | ||
| Q4 24 | $-8.64 | $2.83 | ||
| Q3 24 | $0.09 | $1.42 | ||
| Q2 24 | $0.04 | $1.19 | ||
| Q1 24 | $-0.02 | $2.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $111.8M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $746.9M |
| Total Assets | $1.1B | $992.3M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $111.8M | ||
| Q3 25 | $70.5M | $97.3M | ||
| Q2 25 | $90.3M | $192.3M | ||
| Q1 25 | $97.0M | $144.5M | ||
| Q4 24 | $107.7M | $324.6M | ||
| Q3 24 | $89.0M | $263.6M | ||
| Q2 24 | $92.2M | $241.3M | ||
| Q1 24 | $75.8M | $196.2M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $746.9M | ||
| Q3 25 | $778.0M | $758.0M | ||
| Q2 25 | $776.3M | $778.0M | ||
| Q1 25 | $839.4M | $780.7M | ||
| Q4 24 | $828.5M | $783.9M | ||
| Q3 24 | $1.2B | $764.1M | ||
| Q2 24 | $1.2B | $759.2M | ||
| Q1 24 | $1.2B | $759.4M |
| Q4 25 | $1.1B | $992.3M | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $1.7B | $992.9M | ||
| Q2 24 | $1.7B | $992.7M | ||
| Q1 24 | $1.7B | $1.0B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $130.5M |
| Free Cash FlowOCF − Capex | $21.3M | $122.9M |
| FCF MarginFCF / Revenue | 11.8% | 39.9% |
| Capex IntensityCapex / Revenue | 3.8% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $238.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $130.5M | ||
| Q3 25 | $14.0M | $-48.6M | ||
| Q2 25 | $6.8M | $124.0M | ||
| Q1 25 | $25.7M | $67.6M | ||
| Q4 24 | $57.9M | $135.8M | ||
| Q3 24 | $23.0M | $-29.4M | ||
| Q2 24 | $27.8M | $98.6M | ||
| Q1 24 | $-8.0M | $85.0M |
| Q4 25 | $21.3M | $122.9M | ||
| Q3 25 | $7.0M | $-58.3M | ||
| Q2 25 | $-4.2M | $115.4M | ||
| Q1 25 | $19.0M | $58.7M | ||
| Q4 24 | $53.1M | $126.1M | ||
| Q3 24 | $20.0M | $-39.0M | ||
| Q2 24 | $21.9M | $89.6M | ||
| Q1 24 | $-12.1M | $76.0M |
| Q4 25 | 11.8% | 39.9% | ||
| Q3 25 | 3.9% | -22.3% | ||
| Q2 25 | -2.4% | 46.6% | ||
| Q1 25 | 11.3% | 20.3% | ||
| Q4 24 | 29.6% | 43.1% | ||
| Q3 24 | 11.7% | -16.3% | ||
| Q2 24 | 12.8% | 39.4% | ||
| Q1 24 | -7.3% | 27.7% |
| Q4 25 | 3.8% | 2.5% | ||
| Q3 25 | 3.9% | 3.7% | ||
| Q2 25 | 6.3% | 3.5% | ||
| Q1 25 | 4.0% | 3.1% | ||
| Q4 24 | 2.7% | 3.3% | ||
| Q3 24 | 1.8% | 4.0% | ||
| Q2 24 | 3.4% | 3.9% | ||
| Q1 24 | 2.5% | 3.3% |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | -2.99× | ||
| Q2 25 | — | 2.98× | ||
| Q1 25 | 3.89× | 0.94× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | 5.35× | -0.71× | ||
| Q2 24 | 15.44× | 2.83× | ||
| Q1 24 | — | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
LOPE
Segment breakdown not available.
